NEW YORK (GenomeWeb) – Clinical genomics interpretation software vendor Congenica is pushing deeper into China by adding Digital China Health Technologies as a strategic partner.
Cambridge, England-based Congenica said today that it will work with the Hong Kong-based company, branded as DCHealth, to tailor its its flagship Sapientia genome analysis platform for the Chinese market. DCHealth, which has a strong presence in Chinese hospitals, will lead the marketing of this localized version of Sapienta, the companies said.
"China is an important market for Congenica, and this new relationship with DCHealth gives us greater insight into what the local market requires to accelerate the broader use of genomic medicine. This comprehensive commercial partnership will give us extensive market insight and access," Congenica CEO David Atkins said in a statement.
"As the provision of routine clinical genomics services continues to increase in China and other global markets, the analysis and interpretation of genomic data will be one of the most challenging aspects of transforming these data into meaningful, clinically actionable results," added DCHealth CEO David Shi.
Congenica had said in early 2017 that it had designs on courting the clinical genetics laboratories, specialists, academics, and biotechnology and pharmaceutical firms in China as potential customers for Sapienta.
Earlier this year, Congenica announced a partnership with FutureNeuro, the Science Foundation Ireland-backed Research Centre for Chronic and Rare Neurological Diseases, to develop new technology to improve diagnosis of genetic epilepsies. They will seek to integrate genomic sequences into electronic health records to augment the imaging that clinicians have historically relied on to diagnose and treat certain forms of epilepsy.